The Chicago Entrepreneur

Alzheimer’s drug Leqembi promises to give patients more time, but they face a long road to treatment

Leqembi’s rollout has been slowed by bottlenecks related to reimbursement uncertainties, diagnostic test requirements and regular brain scans, among others.

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous post Nelson Peltz steps down as chair of Wendy’s board, starting a new era for burger chain
Next post Summit Therapeutics’ stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trial